Grifols (GRFS) Return on Capital Employed (2011 - 2020)

Grifols' (GRFS) quarterly Return on Capital Employed came in at 32.1% in Q1 2020, up 8.37% on a QoQ basis from 29.62% in Q4 2019.

Grifols (GRFS) Return on Capital Employed (2011 - 2020) Analysis & Trends

Grifols (GRFS) has 10 years of Return on Capital Employed data on file, last reported at 32.1% in Q1 2020.

Quarterly Return on Capital Employed changed N/A year-over-year to 32.1% in Q1 2020, while the trailing twelve-month figure through Mar 2020 was 32.1% (changed N/A YoY) and the FY2025 annual result came in at 15.79%, down 163834.0% from the prior year.
Return on Capital Employed advanced to 32.1% in Q1 2020, from 29.62% in the prior quarter.
In the past five years, Return on Capital Employed ranged from a high of 32.1% in Q1 2020 to a low of 13.15% in Q4 2016.
A 5-year average of 18.6% and a median of 16.16% in 2016 frame the typical range for Return on Capital Employed.
Annual changes were most pronounced in 2016 — Return on Capital Employed tumbled 409 bps — and 2019, when it jumped 1518 bps.
Tracing GRFS's Return on Capital Employed over 5 years: stood at 13.15% in 2016, then soared by 35 bps to 17.7% in 2017, then declined by 18 bps to 14.44% in 2018, then soared by 105 bps to 29.62% in 2019, then gained by 8 bps to 32.1% in 2020.
The last three Return on Capital Employed figures came in at 32.1% (Q1 2020), 29.62% (Q4 2019), and 14.44% (Q4 2018), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Johnson & Johnson	654.62 Bn	633.86 Bn	17.26 Bn	17.83%
2	AbbVie	471.49 Bn	464.92 Bn	12.70 Bn	17.92%
3	Merck	380.76 Bn	373.62 Bn	12.21 Bn	9.96%
4	Novartis Ag	303.50 Bn	295.81 Bn	11.24 Bn	-
5	Astrazeneca	258.69 Bn	253.79 Bn	12.86 Bn	16.76%
6	Amgen	237.83 Bn	223.84 Bn	7.24 Bn	16.66%
7	Gilead Sciences	183.09 Bn	179.91 Bn	6.22 Bn	-5.97%
8	Pfizer	161.60 Bn	149.90 Bn	10.94 Bn	11.86%
9	Gsk	105.97 Bn	101.81 Bn	8.24 Bn	11.42%
10	Grifols	5.47 Bn	4.47 Bn	-	-

Download Data